| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $5,000,000 | 1 | 100 |
Sells | $0 | 0 | 0 |
| ORBIMED ADVISORS LLC | 10 percent owner | 1 | $5M | 0 | $0 | $5M |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Over the last 12 months, insiders at Adicet Bio, Inc. have bought $5M and sold $0 worth of Adicet Bio, Inc. stock.
On average, over the past 5 years, insiders at Adicet Bio, Inc. have bought $9.42M and sold $2.2M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC (10 percent owner) — $5M.
The last purchase of 5,000,000 shares for transaction amount of $5M was made by ORBIMED ADVISORS LLC (10 percent owner) on 2025‑10‑08.
| 2025-10-08 | ORBIMED ADVISORS LLC | 10 percent owner | 5M 6.4668% | $1.00 | $5M | +6.60% | ||
| 2024-06-05 | Sale | Kauffman Michael | director | 5,900 0.0071% | $1.43 | $8,437 | -29.86% | |
| 2024-01-25 | ORBIMED ADVISORS LLC | 3.13M 7.0488% | $2.40 | $7.5M | -41.70% | |||
| 2024-01-25 | GORDON CARL L | 3.13M 7.0488% | $2.40 | $7.5M | -41.70% | |||
| 2023-10-02 | Schor Chen | President & CEO | 5,500 0.013% | $1.33 | $7,340 | +13.74% | ||
| 2023-09-29 | Sale | Schor Chen | President & CEO | 5,500 0.0127% | $1.36 | $7,481 | +9.12% | |
| 2023-09-28 | Sale | Schor Chen | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +4.93% | |
| 2023-09-28 | Schor Chen | President & CEO | 5,500 0.0128% | $1.42 | $7,810 | +4.93% | ||
| 2023-06-30 | DUBIN STEVE | director | 5,000 0.0115% | $2.40 | $12,000 | -27.78% | ||
| 2023-06-27 | ORBIMED ADVISORS LLC | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | |||
| 2023-06-27 | GORDON CARL L | 875,000 1.9987% | $2.09 | $1.83M | -16.90% | |||
| 2023-02-15 | Sale | Healey Don | Chief Technology Officer | 4,533 0.0101% | $7.57 | $34,327 | -68.06% | |
| 2023-02-10 | Sale | Healey Don | Chief Technology Officer | 10,467 0.0247% | $7.98 | $83,476 | -68.37% | |
| 2022-11-10 | Sale | Schor Chen | President & CEO | 39,955 0.095% | $20.30 | $811,242 | -72.57% | |
| 2022-11-10 | Sale | Aftab Blake | Chief Scientific Officer | 6,967 0.0171% | $21.00 | $146,307 | -72.57% | |
| 2022-11-07 | Sale | Schor Chen | President & CEO | 30,000 0.0726% | $19.05 | $571,488 | -69.94% | |
| 2022-11-03 | Sale | Schor Chen | President & CEO | 24,813 0.06% | $18.04 | $447,718 | -68.15% | |
| 2022-11-02 | Sale | Schor Chen | President & CEO | 500 0.0013% | $18.00 | $9,000 | -66.45% | |
| 2022-10-19 | Sale | Aftab Blake | Chief Scientific Officer | 8,067 0.0198% | $16.27 | $131,250 | -62.28% | |
| 2022-10-12 | Sale | Aftab Blake | Chief Scientific Officer | 1,646 0.0039% | $15.40 | $25,348 | -61.43% |
| ORBIMED ADVISORS LLC | 10 percent owner | 9026359 94.2359% | $74.74M | 4 | 0 | <0.0001% |
| GORDON CARL L | 7526359 78.5758% | $62.32M | 2 | 0 | <0.0001% | |
| SILVERSTEIN JONATHAN | 4830387 50.4296% | $40M | 1 | 0 | ||
| PureTech Health LLC | 10 percent owner | 2119696 22.1298% | $17.55M | 1 | 6 | |
| Sinclair Andrew | director | 2115385 22.0848% | $17.52M | 1 | 0 | <0.0001% |
| Jakobovits Aya | 356343 3.7202% | $2.95M | 0 | 10 | ||
| Healey Don | Chief Technology Officer | 66568 0.695% | $551,183.04 | 0 | 2 | |
| Galimi Francesco | SVP & Chief Medical Officer | 59917 0.6255% | $496,112.76 | 0 | 1 | |
| Schor Chen | President & CEO | 43469 0.4538% | $359,923.32 | 5 | 18 | +9.34% |
| Aftab Blake | Chief Scientific Officer | 28209 0.2945% | $233,570.52 | 0 | 6 | |
| DUBIN STEVE | director | 10900 0.1138% | $90,252.00 | 1 | 0 | <0.0001% |
| Kauffman Michael | director | 5900 0.0616% | $48,852.00 | 0 | 1 |
$30,470,407 | 140 | 20.39% | $98.55M | |
$103,288,323 | 51 | 4.78% | $68.9M | |
$693,326 | 47 | -16.18% | $69.17M | |
$4,898,715 | 46 | 40.75% | $81.46M | |
$77,146,704 | 43 | 13.28% | $93.15M | |
$909,129 | 37 | 42.19% | $100.12M | |
$167,514,690 | 24 | -2.23% | $99.88M | |
$1,602,584 | 20 | 15.26% | $78.63M | |
$33,128,160 | 18 | -13.64% | $83.89M | |
$6,733,543 | 17 | -19.02% | $73.92M | |
$277,862 | 15 | 59.79% | $74.29M | |
$145,194 | 11 | -27.37% | $79.44M | |
$9,999,920 | 10 | -40.03% | $82.68M | |
$280,338 | 8 | 34.18% | $69.62M | |
Adicet Bio, Inc. (ACET) | $32,684,649 | 8 | -15.84% | $79.31M |
$110,013 | 5 | 6.58% | $71.11M | |
$762,555 | 4 | -34.52% | $83.12M | |
$401,951 | 4 | 57.41% | $78.35M | |
$12,498 | 2 | 39.61% | $73.23M |
| Increased Positions | 24 | +41.38% | 147,738 | +4.33% |
| Decreased Positions | 20 | -34.48% | 196,057 | -5.75% |
| New Positions | 11 | New | 33,672 | New |
| Sold Out Positions | 8 | Sold Out | 83,201 | Sold Out |
| Total Postitions | 62 | +6.9% | 3M | -1.42% |
| Orbimed Advisors Llc | $6,310.00 | 7.15% | 715,446 | 0 | 0% | 2025-09-30 |
| Tang Capital Management Llc | $4,533.00 | 5.14% | 513,976 | 0 | 0% | 2025-09-30 |
| Ra Capital Management, L.P. | $4,157.00 | 4.71% | 471,313 | 0 | 0% | 2025-09-30 |
| Goldman Sachs Group Inc | $2,068.00 | 2.35% | 234,476 | -30 | -0.01% | 2025-09-30 |
| Vanguard Group Inc | $1,804.00 | 2.05% | 204,533 | 0 | 0% | 2025-09-30 |
| Carlyle Group Inc. | $1,625.00 | 1.84% | 184,295 | 0 | 0% | 2025-09-30 |
| Aquilo Capital Management, Llc | $1,354.00 | 1.54% | 153,512 | -4,688 | -2.96% | 2025-03-31 |
| Acadian Asset Management Llc | $1,249.00 | 1.42% | 141,593 | +11,930 | +9.2% | 2025-09-30 |
| Renaissance Technologies Llc | $1,008.00 | 1.14% | 114,309 | +42,195 | +58.51% | 2025-09-30 |
| Regeneron Pharmaceuticals, Inc. | $534.00 | 0.61% | 60,511 | 0 | 0% | 2025-09-30 |